Koller: Broad patient targeting to maximize revenue causes drug trial failures
Daphne Koller · No Priors Ep. 6 | With Daphne Koller from Insitro · May 19, 2023 · at 28:23
Daphne Koller, founder and CEO of Insitro, explains why pharmaceutical companies fail clinical trials by avoiding patient stratification.
0:00 / 0:15exact quote · 15.1s
▶ Watch the full episode on YouTube → 720p mp4 · rendered on demand · StarZero watermark
“That is one of the big things that causes drugs to fail is that you are trying to apply it more broadly. If I'm being cynical, sometimes it's supposed to maximize the revenues that you can get from a drug versus trying to figure out exactly in which patients it's going to work.”
quote is from the automated transcript, cleaned for reading: filler sounds and stutters are removed, nothing is rephrased. names can be misheard (the analysis reads context, assessments check outside sources). how →
More from Daphne Koller
Koller: AI requires synthesizing deep learning with causal and interpretable modeling
“What I think we're starting to see right now is a the pendulum starting to swing back in the sense that there is a greater understanding that you really need a bit of both. You need that hugely powerful pattern recognition that we get from deep learning, but y…”
Koller: AI requires synthesizing deep learning with causal and interpretable models
“What I think we're starting to see right now is a the pendulum starting to swing back in the sense that there is a greater understanding that you really need a bit of both. You need that hugely powerful pattern recognition that we get from deep learning, but y…”
Koller: Tech workers entering biotech often disrespect biological challenges and create friction
“There's a lot of tech people who come in To life sciences, and it's like, we have that cell verbal. We are the smartest. We're machine learning. We're going to solve everything. And they don't respect the challenges of the other discipline. They sometimes don'…”
Koller: Most drug failures stem from wrong target selection, not trial design
“It's a place where most programs fail is because we're just not modulating the right thing. It's the wrong target in the wrong indication or the wrong patient population.”